{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "11180019", "DateCompleted": {"Year": "2001", "Month": "01", "Day": "18"}, "DateRevised": {"Year": "2024", "Month": "01", "Day": "09"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "0009-9236", "JournalIssue": {"Volume": "68", "Issue": "6", "PubDate": {"Year": "2000", "Month": "Dec"}}, "Title": "Clinical pharmacology and therapeutics", "ISOAbbreviation": "Clin Pharmacol Ther"}, "ArticleTitle": "St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.", "Pagination": {"StartPage": "598", "EndPage": "604", "MedlinePgn": "598-604"}, "Abstract": {"AbstractText": ["St John's Wort (hypericum perforatum) is an herbal medicine that is frequently used for therapy of mild depression. Recently, St John's Wort was reported to substantially decrease blood/plasma concentrations and efficacy of cyclosporine (INN, ciclosporin), indinavir, and digoxin. In this study we investigated the mechanisms of these St John's Wort-induced drug interactions.", "In a preclinical study, the administration of St John's Wort extract to rats during 14 days resulted in a 3.8-fold increase of intestinal P-glycoprotein/Mdrl expression and in a 2.5-fold increase in hepatic CYP3A2 expression (Western blot analyses). In a clinical study, the administration of St John's Wort extract to 8 healthy male volunteers during 14 days resulted in an 18% decrease of digoxin exposure after a single digoxin dose (0.5 mg), in 1.4- and 1.5-fold increased expressions of duodenal P-glycoprotein/MDR1 and CYP3A4, respectively, and in a 1.4-fold increase in the functional activity of hepatic CYP3A4 (14C-erythromycin breath test).", "These results indicate direct inducing effects of St John's Wort on intestinal P-glycoprotein/MDR1 (in rats and humans), hepatic CYP3A2 (in rats), and intestinal and hepatic CYP3A4 (in humans). Therefore the results provide a mechanistic explanation for the previously observed drug interactions in patients and support the importance of intestinal P-glycoprotein/MDR1 in addition to intestinal and hepatic CYP3A4 for overall drug absorption and disposition in humans."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine, Institute of Clinical  Chemistry, Z\u00fcrich, Switzerland."}], "Identifier": [], "LastName": "D\u00fcrr", "ForeName": "D", "Initials": "D"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Stieger", "ForeName": "B", "Initials": "B"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Kullak-Ublick", "ForeName": "G A", "Initials": "GA"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Rentsch", "ForeName": "K M", "Initials": "KM"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Steinert", "ForeName": "H C", "Initials": "HC"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Meier", "ForeName": "P J", "Initials": "PJ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Fattinger", "ForeName": "K", "Initials": "K"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Clin Pharmacol Ther", "NlmUniqueID": "0372741", "ISSNLinking": "0009-9236"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "ATP Binding Cassette Transporter, Subfamily B, Member 1"}, {"RegistryNumber": "0", "NameOfSubstance": "Cardiotonic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "73K4184T59", "NameOfSubstance": "Digoxin"}, {"RegistryNumber": "9035-51-2", "NameOfSubstance": "Cytochrome P-450 Enzyme System"}, {"RegistryNumber": "EC 1.-", "NameOfSubstance": "Mixed Function Oxygenases"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "CYP3A protein, human"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Cytochrome P-450 CYP3A"}, {"RegistryNumber": "EC 1.14.14.55", "NameOfSubstance": "CYP3A4 protein, human"}], "MeshHeadingList": [{"QualifierName": ["biosynthesis"], "DescriptorName": "ATP Binding Cassette Transporter, Subfamily B, Member 1"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Biological Availability"}, {"QualifierName": ["pharmacokinetics"], "DescriptorName": "Cardiotonic Agents"}, {"QualifierName": [], "DescriptorName": "Cytochrome P-450 CYP3A"}, {"QualifierName": ["biosynthesis"], "DescriptorName": "Cytochrome P-450 Enzyme System"}, {"QualifierName": ["pharmacokinetics"], "DescriptorName": "Digoxin"}, {"QualifierName": [], "DescriptorName": "Drug Interactions"}, {"QualifierName": ["drug effects", "enzymology", "metabolism"], "DescriptorName": "Duodenum"}, {"QualifierName": ["drug effects"], "DescriptorName": "Enzyme Induction"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Hypericum"}, {"QualifierName": ["drug effects", "enzymology", "metabolism"], "DescriptorName": "Intestine, Small"}, {"QualifierName": ["drug effects", "enzymology"], "DescriptorName": "Liver"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["biosynthesis"], "DescriptorName": "Mixed Function Oxygenases"}, {"QualifierName": ["adverse effects", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2001", "Month": "2", "Day": "17", "Hour": "11", "Minute": "0"}, {"Year": "2001", "Month": "2", "Day": "28", "Hour": "10", "Minute": "1"}, {"Year": "2001", "Month": "2", "Day": "17", "Hour": "11", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["11180019", "10.1067/mcp.2000.112240", "S0009-9236(00)67567-7"]}}], "PubmedBookArticle": []}